Land: Niederlande
Sprache: Niederländisch
Quelle: CBG-MEB (College ter Beoordeling van Geneesmiddelen)
ZOLEDRONINEZUUR 1-WATER SAMENSTELLING overeenkomend met ; ZOLEDRONINEZUUR 0-WATER
GENERICON PHARMA Gesellschaft m.b.H. Hafnerstrasse 211 A-8054 GRAZ (OOSTENRIJK)
M05BA08
Zoledronic acid 1-WATER COMPOSITION corresponding to ; zoledronic acid 0-WATER
Oplossing voor infusie
MANNITOL (D-) (E 421) ; STIKSTOF (HEAD SPACE) (E 941) ; TRINATRIUMCITRAAT 2-WATER (E 331) ; WATER VOOR INJECTIE,
Intraveneus gebruik
Zoledronic Acid
Hulpstoffen: MANNITOL (D-) (E 421); STIKSTOF (HEAD SPACE) (E 941); TRINATRIUMCITRAAT 2-WATER (E 331); WATER VOOR INJECTIE;
2013-08-12
1 PACKAGE LEAFLET: INFORMATION FOR THE USER Zoledroninezuur Genericon 4mg/100ml, oplossing voor infusie Zoledronic acid READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Zoledroninezuur Genericon is and what it is used for 2. What you need to know before you are given Zoledroninezuur Genericon 3. How Zoledroninezuur Genericon is used 4. Possible side effects 5. How to store Zoledroninezuur Genericon 6. Contents of the pack and other information 1. WHAT ZOLEDRONINEZUUR GENERICON IS AND WHAT IT IS USED FOR The active substance in Zoledroninezuur Genericon is zoledronic acid, which belongs to a group of substances called bisphosphonates. Zoledronic acid works by attaching itself to the bone and slowing down the rate of bone change. It is used: • TO PREVENT BONE COMPLICATIONS, e.g. fractures, in adult patients with bone metastases (spread of cancer from primary site to the bone). • TO REDUCE THE AMOUNT OF CALCIUM in the blood in adult patients where it is too high due to the presence of a tumour. Tumours can accelerate normal bone change in such a way that the release of calcium from bone is increased. This condition is known as tumour-induced hypercalcaemia (TIH). 2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN ZOLEDRONINEZUUR GENERICON Follow carefully all instructions given to you by your doctor. Your doctor will carry out blood tests before you start treatment with Zoledroninezuur Genericon and will check your response to treatment at regular intervals. YOU SHOULD NOT BE GIVEN ZOLEDRONINEZUUR GENERICON: − if you are breast-feeding. − if you are allergic (hypersensitive) to zoledronic acid, another bisphosphonate (the group of su Lesen Sie das vollständige Dokument
1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Zoledroninezuur Genericon 4 mg/100 ml, oplossing voor infusie 2. QUALITATIVE AND QUANTITAVE COMPOSITION One vial contains 4 mg zoledronic acid, corresponding to 4.26 mg zoledronic acid monohydrate. This medicinal product contains less than 1 mmol sodium (23 mg) per infusion, i.e. essentially ’sodium-free’. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for infusion Clear and colourless solution pH: 5.5-7.0 Osmolarity: 0.27-0.33 Osmol /kg 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS - Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone. - Treatment of adult patients with tumour-induced hypercalcaemia (TIH). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Zoledroninezuur Genericon must only be prescribed and administered to patients by healthcare professionals experienced in the administration of intravenous bisphosphonates. Patients treated with Zoledroninezuur Genericon should be given the package leaflet and the patient reminder card. Posology _Prevention of skeletal related events in patients with advanced malignancies involving _ _bone _ _Adults and elderly _ 2 The recommended dose in the prevention of skeletal related events in patients with advanced malignancies involving bone is 4 mg zoledronic acid every 3 to 4 weeks. Patients should also be administered an oral calcium supplement of 500 mg and 400 IU vitamin D daily. The decision to treat patients with bone metastases for the prevention of skeletal related events should consider that the onset of treatment effect is 2-3 months. _Treatment of TIH _ _Adults and elderly _ The recommended dose in hypercalcaemia (albumin-corrected serum calcium ≥ 12.0 mg/dl or 3.0 mmol/l) is a single dose of 4 mg zoledronic acid. _Renal impairment _ _TIH: _ Zoledroninezuur Genericon treatment in TIH patients who al Lesen Sie das vollständige Dokument